AJBB Cover
Frequency: Quarterly
ISSN: 1553-3468 (Print)
ISSN: 1558-6332 (Online)
Letter to the Editor Open Access

Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug

Mohamed Nabil Ibrahim1 and Abdo Abdellah Elfiky2
  • 1 Jouf University, Saudi Arabia
  • 2 Cairo University, Egypt

Abstract

The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

American Journal of Biochemistry and Biotechnology
Volume 17 No. 2, 2021, 205-207

DOI: https://doi.org/10.3844/ajbbsp.2021.205.207

Submitted On: 2 March 2021 Published On: 10 May 2021

How to Cite: Ibrahim, M. N. & Elfiky, A. A. (2021). Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug. American Journal of Biochemistry and Biotechnology, 17(2), 205-207. https://doi.org/10.3844/ajbbsp.2021.205.207

Open AccessCopyright: © 2021 Mohamed Nabil Ibrahim and Abdo Abdellah Elfiky. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • 2,999 Views
  • 1,398 Downloads
  • 0 Citations

Download

Keywords

  • Sofosbuvir-COVID-19-RNA Polymerase-Therapy